Lung Cancer Study Group

Molecular Tumor Board

The session “Molecular Tumor Board – when and how to diagnose and treat rarer mutations in patients with NSCLC”, of the 10th GECP Congress/ 1st Portuguese Congress of Lung Cancer, had the perspective of Dr.ª Sónia Silva about MET inhibitor use.

The specialist says that molecular alterations in lung cancer are more and more a reality, but fortunately there are already approved drugs that will make a difference in these patients. Dr. Sónia Silva also talks about the future, referring that “these new therapeutic targets are fundamental in the treatment of patients with poor prognosis” due to their greater efficacy and lower toxicity.

Watch the full video and get to know the expert’s perspective.

Posted in congressos, notícias, vídeo
©2022 Copyright GECP